Please use this identifier to cite or link to this item:
http://hdl.handle.net/123456789/26347
Title: | Updates on dengue vaccine and antiviral: Where are we heading? |
Authors: | Norshidah, Harun Vignesh, Ramachandran Lai, Ngit Shin (UniKL RCMP) |
Keywords: | Antiviral Dengue virus Drug discovery NS2B/NS3pro Vaccine |
Issue Date: | Nov-2021 |
Publisher: | MDPI |
Citation: | Norshidah, H., Vignesh, R., & Lai, N. S. (2021). Updates on Dengue Vaccine and Antiviral: Where Are We Heading? Molecules, 26(22), 6768. https://doi.org/10.3390/molecules26226768 |
Abstract: | Approximately 100–400 million people from more than 100 countries in the tropical and subtropical world are affected by dengue infections. Recent scientific breakthroughs have brought new insights into novel strategies for the production of dengue antivirals and vaccines. The search for specific dengue inhibitors is expanding, and the mechanisms for evaluating the efficacy of novel drugs are currently established, allowing for expedited translation into human trials. Furthermore, in the aftermath of the only FDA-approved vaccine, Dengvaxia, a safer and more effective dengue vaccine candidate is making its way through the clinical trials. Until an effective antiviral therapy and licensed vaccine are available, disease monitoring and vector population control will be the mainstays of dengue prevention. In this article, we highlighted recent advances made in the perspectives of efforts made recently, in dengue vaccine development and dengue antiviral drug. |
URI: | https://www.mdpi.com/1420-3049/26/22/6768 http://hdl.handle.net/123456789/26347 |
ISSN: | 14203049 |
Appears in Collections: | Journal Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
molecules-26-06768.pdf | 2.56 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.